Project Summary

Project Name Promoting cervical cancer prevention through early detection and treatment
Initiatives for Sustainable Development Goals (SDGs) Goal 3: Ensure healthy lives and promote well-being for all at all ages
  • 3.4 By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being
  • 3.7 By 2030, ensure universal access to sexual and reproductive health-care services, including for family planning, information and education, and the integration of reproductive health into national strategies and programmes
    • Goal 5: Achieve gender equality and empower all women and girls
    Ensure universal access to sexual and reproductive health and rights (in accordance with the International Conference on Population and Development (ICPD) Program of Action and the Beijing Platform for Action and the outcomes of their review conferences)
Outline of the Project
Target: This project aims to increase in access to quality screening and treatment for cervical cancer and the HPV vaccine
  • Provide accurate information on cervical cancer to community people (especially, men and women aged 10-49)
  • Establish a cervical cancer screening and treatment system
  • Strengthen the referral system for cervical cancer screening and treatment
Region 3 areas (Makadara, Kamukunji, and Langata) of Nairobi County, Republic of Kenya
Duration July 2022 to June 2025 (3 years)
Partner JOICFP

Implementation Structure

KPIs

Indicators and Output 3 year Target Before Project Implementation
(2021/7～2022/6)		 1st year
(2022/7～2023/7)		 2nd year
(2023/8～2024/7)		 3rd year
(2024/8～2025/6)
1. Number of women tested for cervical cancer 137,545 13,814 23,502
2. Number of women who were screened for cervical cancer and received treatment/care 1,238 52 89
3. Number of HPV vaccine received (9-14 age) 44,157 8,857 17,696
Indicators and Outcome 3 year Target 1st year 2nd year 3rd year
1. Cervical cancer screening test participation rate 38% 23% (Baseline)
2. Consultation rate for cervical precancerous lesion treatment 38% 23% (Baseline)
3. HPV vaccine uptake rate 38% 28% (Baseline)